Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02387268
Other study ID # CL00005
Secondary ID
Status Completed
Phase N/A
First received March 2, 2015
Last updated August 22, 2017
Start date May 2015
Est. completion date November 2015

Study information

Verified date February 2016
Source Motus GI Medical Technologies Ltd
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The Motus GI Colon Cleansing device is intended to facilitate intra-procedural cleaning of a poorly prepared colon by irrigating the colon and evacuating the irrigation fluid and feces.


Description:

The study aim to evaluate the post Procedure Cleansing Level as Measured by the Boston Bowel Preparation Scale (BBPS).

Each subject was required to follow a bowel preparation regimen including split dose of 2 tablets of 5mg Bysacodyle followed by a colonoscopy procedure with the tested device.


Recruitment information / eligibility

Status Completed
Enrollment 10
Est. completion date November 2015
Est. primary completion date June 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

1. Subjects in the age range of 18-75 years

2. Subjects with BMI within the range of 18.5-35

3. Subject is willing to sign informed consent form

Exclusion Criteria:

1. Active or severe inflammatory bowel disease (IBD)

2. Subjects with severe diverticulitis \ diverticular disease (known or detected)

3. Known or detected colonic stenosis

4. Known or detected bowel obstruction

5. History of prior colon surgery

6. ASA=IV (sever systemic disease)

7. Sever Renal insufficiency (Creatinine=1.5mg%)

8. Sever Liver insufficiency (ALT/AST=2UNL)

9. Contraindication for "colonoscopy" anesthesia \ sedation \ prep agent

10. pregnancy

11. Subjects with altered mental status/inability to provide informed consent

12. Subject has a condition or is in a situation which in the investigators opinion may put the subject at significant risk, may confound the study results, or may interfere significantly

Study Design


Intervention

Device:
CleanC system
Cleansing liquid and fecal matter during a standard colonoscopy procedure

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
Motus GI Medical Technologies Ltd

Outcome

Type Measure Description Time frame Safety issue
Primary Percentage Subjects With Post Procedure Cleansing Level as Measured by the Boston Bowel Preparation Scale (BBPS) Adequate Cleansing-(BBPS>1 ) Scale ranges- Min-0, Max-3 where:
0 = Unprepared colon segment with mucosa not seen due to solid stool that cannot be cleared.
= Portion of mucosa of the colon segment seen, but other areas of the colon segment not well seen due to staining, residual stool and/or opaque liquid.
= Minor amount of residual staining, small fragments of stool and/or opaque liquid, but mucosa of colon segment seen well.
= Entire mucosa of colon segment seen well with no residual staining, small fragments of stool or opaque liquid. The wording of the scale was finalized after incorporating feedback from three colleagues experienced in colonoscopy.
During the colonoscopy procedure withdrawal phase (10 min in average)
Primary Safety as Measured by Number of Serious Adverse Events and Major Complications. Max of 9 days
Secondary Percentage of Participants in Whom the Cecum Was Reached A procedure was considered complete when the cecum was reached and visualized. During the colonoscopy procedure